Teva and Alvotech launch the first interchangeable high-concentration.

Teva Pharmaceuticals and Alvotech have announced the availability of SIMLANDI (adalimumab-ryvk), the first interchangeable high-concentration, citrate-free biosimilar to Humira, in the US. It is indicated for the treatment of various autoimmune conditions like rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and uveitis.

May 21, 2024
7 Articles